US FDA Seeks Ways To Prevent NonResponders From Sinking TissueAgnostic Indications

US FDA Seeks Ways To Prevent Non-Responders From Sinking Tissue-Agnostic Indications

Agency officials and oncologists debate considerations where a data package overwhelms non-responders in favor of a tissue-agnostic indication.

More From BioPortfolio on "US FDA Seeks Ways To Prevent Non-Responders From Sinking Tissue-Agnostic Indications"